These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 10096531)

  • 41. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lessons from cyclosporine monotherapy in renal transplantation: the impact of acute rejection on long-term allograft outcome.
    Coll E; Crespo M; Solé M; Campistol JM; Cofàn F; Esforzado N; Ricart MJ; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2004 Mar; 36(2 Suppl):114S-116S. PubMed ID: 15041318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A; Arlen D; Barrett B; Boucher A; Cardella C; Cockfield SM; Rush D; Paraskevas S; Shapiro J; Shoker A; Yilmaz S; Zaltzman JS; Kiberd B
    Transplantation; 2008 Oct; 86(7):953-60. PubMed ID: 18852662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months.
    Aichberger C; Eberl T; Riedmann B; Pernthaler H; Ofner D; Königsrainer A; Margreiter R
    Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
    Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients.
    Kuo PC; Luikart H; Busse-Henry S; Hunt SA; Valantine HA; Stinson EB; Oyer PE; Scandling JD; Alfrey EJ; Dafoe DC
    Clin Transplant; 1995 Apr; 9(2):92-7. PubMed ID: 7599409
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A blinded retrospective analysis of renal allograft pathology using the Banff schema: implications for clinical management.
    Dean DE; Kamath S; Peddi VR; Schroeder TJ; First MR; Cavallo T
    Transplantation; 1999 Sep; 68(5):642-5. PubMed ID: 10507482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome.
    Bates WD; Davies DR; Welsh K; Gray DW; Fuggle SV; Morris PJ
    Nephrol Dial Transplant; 1999 Oct; 14(10):2364-9. PubMed ID: 10528659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
    Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
    Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved clinical outcomes in Chinese renal allograft recipients receiving lower dose immunosuppressants.
    Wu JY; Chen JH; Wang YM; He Q; Wu DB
    Transplantation; 2004 Sep; 78(5):713-8. PubMed ID: 15371674
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL; Ramos E; Lin A; Vincenti F;
    Transplantation; 2001 Aug; 72(4):642-7. PubMed ID: 11544424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.
    Koziolek MJ; Riess R; Geiger H; Thévenod F; Hauser IA
    Kidney Int; 2001 Jul; 60(1):156-66. PubMed ID: 11422747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of biopsy in kidney transplants with delayed graft function and acute dysfunction.
    Silva DM; Garcia JP; Ribeiro AR; Veronese FJ; Edelweiss MI; Gonçalves LF; Manfro RC
    Transplant Proc; 2007 Mar; 39(2):376-7. PubMed ID: 17362734
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ten-year protocol biopsy findings of renal allografts in the calcineurin inhibitor era.
    Okamoto M; Akioka K; Ushigome H; Higuchi A; Nobori S; Ogino S; Uryuhara K; Kaihara S; Hatta T; Urasaki K; Yoshimura N
    Clin Transplant; 2006; 20 Suppl 15():16-9. PubMed ID: 16848870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.